Novartis Ag

Speedel Pharma Ag

Ciba-geigy Corporation

Speedel Experimenta Ag

Novartis Corporation

Novartis Pharma Ag

Stefan Stutz

Peter Herold

Robert Mah

Vincenzo Tschinke

Aleksandar Stojanovic

Christiane Marti

Michael Siegfried Quirmbach

Pascal Furet

Keiichi Masuya

Philipp Holzer

Dirk Behnke

Stjepan Jelakovic

Nathalie Jotterand

Pascal Rigollier

Joerg Kallen

Nissim Claude Cohen

Walter Schilling

Yasuchika Yamaguchi

Vito Guagnano

Andrea Vaupel

Richard Goschke

Felix Spindler

Nicole Buschmann

Achim Schlapbach

Marc Gerspacher

Edgar Jacoby

Adriano Indolese

Simona Cotesta

Joerg Berghausen

Bo Tong Liu

Clive McCarthy

Rainer Machauer

Catherine Leblanc

Lv Liao

Joseph Schoepfer

Andreas Von Sprecher

Edwige Liliane Jeanne Lorthiois

Christoph Schumacher

Silvio Roggo

Bo Liu

Jurgen Klaus Maibaum

Bibia Bennacer

Haixia Ren

Walter Weissensteiner

Thomas Sturm

J Urgen Maibaum

Richard G Oschke

Isabelle Lyothier

Liang Mao

Carole Pissot Soldermann

Zenon D Konteatis

Frank Peter Hollinger

Francois Gessier

François Gessier

Rainer Wilcken

Jennifer Lee Ludington

Christophe Mura

Joanna Hergovich Lisztwan

Nadine Schneider

Nicolas Warin

Michael Quirmbach

Frank Hollinger

Jennifer L Ludington

The present invention provides a compound of formula (I) or a stereoisomer thereof, or an atropisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a stereoisomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof; a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.

Pyrazolyl derivatives useful as anti-cancer agents

The invention relates to compounds of formula (I): as described herein, pharmaceutical preparations comprising such compounds, uses and methods of use for such compounds in the treatment of a disorder or a disease mediated by the activity of MDM2 and/or MDM4, and combinations comprising such compounds.

Pyrrolopyrrolidinone compounds

The invention relates to substituted nitrogen containing bicyclic heterocycles of the formula (I) wherein Z is CHor N&#x2014;Rand X, R, R, R, R, Rand n are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of MDM2 and/or MDM4, or variants thereof.

Substituted isoquinolinones and quinazolinones

The invention relates to compounds of formula (I) as described herein, pharmaceutical preparations comprising such compounds, uses and methods of use for such compounds in the treatment of a disorder or a disease mediated by the activity of MDM2 and/or MDM4, and combinations comprising such compounds. 

Pyrazolopyrrolidine compounds

The invention relates to compounds of formula (I): as defined in the application. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of MDM2 and/or MDM4, or variants thereof.

Cyclohexyl isoquinolinone compounds

The invention relates to compounds of formula (I): as defined in the application. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of MDM2 and/or MDM4, or variants thereof. 

Hydroxy substituted isoquinolinone derivatives

Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases

The invention relates to compounds of formula (I) and salts thereof wherein the substituents are as defined in the specification, the application of a compound of formula (I) in a process for the treatment of the human or animal body, in particular with regard to C-Met tyrosine kinase mediated disease; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharmaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner; processes for the preparation of a compound of formula (I).

3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives

The patent application relates to new heterocyclic compounds of the general formula (I), in which R, R, R, Q, T, n and p have the definitions elucidated in more detail in the description, to a process for preparing them and to the use of these compounds as medicaments, particularly as aldosterone synthase inhibitors. 

Heterocyclic spiro-compounds

Heterocyclic compounds of the general formula (I) are provided in which R, R, R, R, Rand n have the definitions elucidated in more detail in the description, to a process for preparing them and to the use of these compounds as medicaments, particularly as aldostereone synthase inhibitors, 

Bis-heterocyclic imidazolyl compounds

Heterocyclic compounds of the formula (I) and salts, preferably pharmaceutically acceptable salts thereof, are provided in which R, R, R, Q, m and n have the meanings explained in detail in the description. Also provided are a process for their preparation and the use of these compounds as medicaments, in particular as aldosterone synthase inhibitors. 

Imidazo compounds

Novel heterocyclic compounds of the general formula (I) and salts, preferably pharmaceutically acceptable salts, thereof, in which R, R, R', Q, m and n have the meanings explained in detail in the description, a process for their preparation and the use of these compounds as medicaments, in particular as aldosterone synthase inhibitors. 

Spiro-imidazo compounds

The application relates to novel heterocyclic compounds of the general formula (I) and salts, preferable pharmaceutically acceptable salts, thereof, in which R, R, R, R, Q, m and n have the meanings explained in detail in the description, a process for their preparation and the use of these compounds as medicaments, in particular as aldosterone synthase inhibitors.

Condensed imidazole derivatives as aldosterone synthase inhibitors

Compounds of the general formula (I) or its salt or a compound in which one or more atoms are replaced by their stable, nonradio-active isotopes, in particular its pharmaceutically acceptable salt; in which X is &#x2014;CH&#x2014;; R is a mono- to tetra-substituted, mono- or bicyclic, unsaturated heterocyclic radical having 1 to 4 nitrogen atoms, Ris Calkyl or Ccycloalkyl; Ris independently of one another H, Calkyl, Calkoxycarbonyl or Calkanoyl; Ris Calkenyl, Calkyl, unsubstituted or substituted aryl-Calkyl or Ccycloalkyl; Ris -L-R; L is Calkylene which is optionally substituted by 1-4 halogen, or a linker: formula (II) n=0, 1 or 2; m=0 or 1; Ris a radical composed of 2 cyclic systems selected from bicyclo[x.y.z]alkyl, spiro[o.p]alkyl, mono- or bioxabicyclo[x.y.z]alkyl or mono- or bioxaspiro[o.p]alkyl, all of which may be substituted by 1-3 substituents selected from Calkyl, Calkoxy, cyano, halogen, Calkoxy-Calkyl, hydroxy-Calkyl or dialkylamino, or if m=0: is also saturated Cheterocyclyl which comprises 1-2 oxygen atoms, substituted by 1-3 substituents selected from Calkyl, Calkoxy, cyano, halogen, Calkoxy-Calkyl, hydroxy-Calkyl or dialkylamino, or if m=1: is also saturated Cheterocyclyl which comprises 1-2 oxygen atoms, optionally substituted by 1-3 substituents selected from Calkyl, Calkoxy, cyano, halogen, C-alkoxy-Calkyl, hydroxy-Calkyl or dialkylamino; have renin-inhibiting properties and can be used as medicines for the treatment of hypertension. 

5-amino-4-hydroxy-7-(imidazo [1,2-A] pyridin-6-ylmethyl)-8-methyl-nonamide derivatives and related compounds as renin inhibitors for the treatment of hypertension

Growing community of inventors

Basel, Switzerland

Stefan Stutz